Autres langues Compass Therapeutics, Inc. OTC Markets

Actions

CMPX

US20454B1044

Recherche biotechnologique et médicale

Temps réel estimé Cboe BZX 16:13:30 05/10/2026			Varia. 5j.	Varia. 1 janv.
0,8990 ^USD	-74,68%		+32,67%	-

23/09	Les actions de Compass Therapeutics reculent après une dégradation de Wedbush	MT
23/09	Compass Therapeutics, Inc. : Wedbush neutre sur le dossier	ZM

Autres langues

23/09	Compass Therapeutics Shares Drop After Downgrade From Wedbush
22/09	Sector Update: Healthcare Stocks Rise Late Afternoon
22/09	Compass Therapeutics Says FDA Recommends New Tovecimig Trial in Biliary Tract Cancer; Shares Fall
22/09	Compass Therapeutics Provides Regulatory Update on Tovecimig in Biliary Tract Cancer Following FDA Feedback
22/09	Compass Therapeutics, Inc. Provides Regulatory Update On Tovecimig In Biliary Tract Cancer Following FDA Feedback
06/08	Compass Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026
06/08	Compass Therapeutics Reports 2026 Second Quarter Financial Results and Provides Corporate Update
17/07	Compass Therapeutics Announces Tovecimig Data Accepted for an Oral Presentation at the ESMO Congress 2026
30/06	A Clinical-Stage Cancer Company Is Putting AI to Work Designing Its Next Generation of Tumor-Targeting Drugs
29/06	Compass Therapeutics, Inc.(NasdaqCM:CMPX) dropped from Russell 3000E Growth Benchmark
29/06	Compass Therapeutics, Inc.(NasdaqCM:CMPX) dropped from Russell 3000 Growth Benchmark
29/06	Compass Therapeutics, Inc.(NasdaqCM:CMPX) dropped from Russell Small Cap Comp Growth Benchmark
29/06	Compass Therapeutics, Inc.(NasdaqCM:CMPX) dropped from Russell Microcap Growth Benchmark Index
29/06	Compass Therapeutics, Inc.(NasdaqCM:CMPX) dropped from Russell 2500 Growth Benchmark
29/06	Compass Therapeutics, Inc.(NasdaqCM:CMPX) dropped from Russell 2000 Growth Benchmark
28/05	Compass Therapeutics to Participate in Upcoming June Investor Events
21/05	Compass Therapeutics to Present Promising Phase 1 Clinical Data for CTX-8371 in Patients with Advanced Malignancies Treated in the Post-Checkpoint Inhibitor Setting at the 2026 ASCO Annual Meeting
12/05	Compass Therapeutics to Participate in Upcoming May Investor Events
05/05	Compass Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026
05/05	Compass Therapeutics Reports 2026 First Quarter Financial Results and Provides Corporate Update
27/04	Compass Therapeutics : 2026 Proxy
27/04	Compass Therapeutics Tovecimig Study Falls Short on Overall Survival Endpoint in Biliary Tract Cancer; Shares Fall Pre-Bell
27/04	Compass Therapeutics Inc. tovecimig plus paclitaxel improves median PFS to 4.7 months versus 2.6 months
27/04	Top Premarket Decliners
27/04	Compass Therapeutics : Corporate Presentation